{"entity":{"id":"compass-therapeutics","kind":"company","name":"Compass Therapeutics","aka":[],"tldr":"Compass makes antibodies that hit two targets at once to reshape the blood supply and immune environment of tumours. Its lead drug, tovecimig, blocks two blood-vessel growth signals and is heading for a possible US approval filing in bile duct cancer.","summary":"Compass Therapeutics is a Boston clinical-stage, oncology-focused company developing antibody-based therapeutics. Lead candidate tovecimig is a DLL4 x VEGF-A bispecific antibody; data from the COMPANION-002 phase 2/3 study in biliary tract cancer were selected for an oral presentation at ESMO 2026, and the company expects FDA feedback in the third quarter of 2026 ahead of a potential BLA filing later in the year. CTX-8371, a PD-1 x PD-L1 bispecific, is in phase 1 cohort expansions in triple-negative breast cancer, Hodgkin lymphoma and non-small cell lung cancer, and CTX-10726, a PD-1 x VEGF-A bispecific, has dosed its first phase 1 patients with initial data expected in the fourth quarter of 2026. A phase 2 study of CTX-471, a CD137 agonist antibody, in NCAM (CD56)-expressing tumours is planned. Compass had $180 million in cash and marketable securities at 30 June 2026, expected to fund operations into 2028. Nasdaq: CMPX.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.compasstherapeutics.com/"},{"label":"Q2 2026 results (8-K exhibit 99.1)","url":"https://www.sec.gov/Archives/edgar/data/1738021/000117184326005292/exh_991.htm"}],"tags":[],"related":[],"cancers":["cholangiocarcinoma","tnbc","hodgkin-lymphoma","nsclc"],"sections":["immunotherapy"],"technologies":["bispecific-antibody","checkpoint-inhibitor","antiangiogenic"],"targets":["vegf","pd1","pdl1"],"drugs":["tovecimig"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["No funding round sourced."],"hq":"Boston, MA","country":"US","companyType":"biotech","website":"https://www.compasstherapeutics.com/","ticker":"CMPX","stage":"public","investors":[],"funding":[]},"route":"/companies/compass-therapeutics/","neighbours":{"cancer":[{"id":"cholangiocarcinoma","kind":"cancer","name":"Biliary tract cancer (cholangiocarcinoma)","route":"/cancers/cholangiocarcinoma/"},{"id":"hodgkin-lymphoma","kind":"cancer","name":"Hodgkin lymphoma","route":"/cancers/hodgkin-lymphoma/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/"}],"section":[{"id":"immunotherapy","kind":"section","name":"Immunotherapy","route":"/fronts/immunotherapy/"}],"technology":[{"id":"antiangiogenic","kind":"technology","name":"Anti-angiogenic therapy","route":"/technologies/antiangiogenic/"},{"id":"bispecific-antibody","kind":"technology","name":"Bispecific antibodies","route":"/technologies/bispecific-antibody/"},{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"target":[{"id":"pd1","kind":"target","name":"PD-1","route":"/targets/pd1/"},{"id":"pdl1","kind":"target","name":"PD-L1","route":"/targets/pdl1/"},{"id":"vegf","kind":"target","name":"VEGF / VEGFR","route":"/targets/vegf/"}],"drug":[{"id":"tovecimig","kind":"drug","name":"Tovecimig","route":"/drugs/tovecimig/"}],"trial":[{"id":"companion-002","kind":"trial","name":"A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002)","route":"/trials/companion-002/"},{"id":"nct07662031","kind":"trial","name":"Tovecimig Plus FOLFIRI in Second Line Metastatic Colorectal Cancer","route":"/trials/nct07662031/"}]}}